Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2017

Open Access 01-12-2017 | Primary Research

MiR-34a and miR-206 act as novel prognostic and therapy biomarkers in cervical cancer

Authors: Ai-Hua Chen, Yu-E Qin, Wen-Fan Tang, Jing Tao, Hua-mei Song, Manzhen Zuo

Published in: Cancer Cell International | Issue 1/2017

Login to get access

Abstract

Background

Recent evidence indicated that the aberrant expression of microRNA plays a crucial role in the development of cervical cancer. The overall shorter survival was strongly related to the abnormal expression of microRNA-34a (miR-34a) and microRNA-206 (miR-206), which target B cell lymphoma-2(Bcl2) and c-Met. Hepatocyte growth factor (HGF)/c-Met pathway is related to the occurrence, development and prognosis of cervical cancer, and c-Met is significantly overexpressed in cervical squamous cell carcinoma. Bcl2 is also considered to be a promising target for developing novel anticancer treatments.

Methods

In this study, we detect the expression of miR-34a and miR-206 in the cervical cancer tissue through quantificational real-time polymerase chain reaction (qRT-PCR) assay, and the expression of Bcl2 and c-Met from cervical cancer tissue were detected by immunohistochemistry.

Results

The expression of miR-34a and miR-206 were down-regulated in the cervical cancer tissue through qRT-PCR assay. As target genes of miR-34a and miR-206, Bcl2 and c-Met were up-regulated in cervical cancer tissues through qRT-PCR assay and immunohistochemistry. Kaplan–Meier and log-rank analysis revealed that down-regulated expression of miR-34a and miR-206 were strongly related to shorter overall survival. Multivariate Cox proportional hazards model for all variables that were statistically significant in the univariate analysis demonstrated that miR-34a (P = 0.038) and miR-206 (P = 0.008) might be independent prognostic factors for overall survival of patients suffering from cervical cancer.

Conclusions

The up-regulation of Bcl2 and c-Met promotes the cervical cancer’s progress, and the expression of miR-34a and miR-206 significantly correlated with the progression and prognosis in cervical cancer. All of these suggested that miR-34a and miR-206 might be the novel prognostic and therapy tools in cervical cancer.
Appendix
Available only for authorised users
Literature
1.
Matsumoto K, Nakamura T. Hepatocyte growth factor (HGF) as a tissue organizer for organogenesis and regeneration. Biochem Biophys Res Commun. 1997;239(3):639–44.CrossRefPubMed
2.
Huntsman D, Resau JH, Klineberg E, et al. Comparison of c-met expression in ovarian epithelial tumors and normal epithelia of the female reproductive tract by quantitative laser scan microscopy. Am J Pathol. 1999;155(2):343–8.CrossRefPubMedPubMedCentral
3.
Furge KA, Zhang Y-W, Vande Woude GF. Met receptor tyrosine kinase: enhanced signaling through adapter proteins. Oncogene. 2000;19(49):5582–9.CrossRefPubMed
4.
Agwa ES, Ma PC. Targeting the MET receptor tyrosine kinase in non-small cell lung cancer: emerging role of tivantinib. Cancer Manag Res. 2014;6:397–404.PubMedPubMedCentral
5.
Yamaguchi R, Yano H, Iemura A, et al. Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology. 1998;28(1):68–77.CrossRefPubMed
6.
Koo BS, Kim JM, Seo ST, et al. Upregulation of HGF and c-MET is associated with subclinical central lymph node metastasis in papillary thyroid microcarcinoma. Ann Surg Oncol. 2014;21(7):2310–7.CrossRefPubMed
7.
Fuse N, Kuboki Y, Kuwata T, et al. Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients. Gastric Cancer. 2016;19(1):183–91.CrossRefPubMed
8.
Neuzillet C, Couvelard A, Tijeras-Raballand A, et al. High c-Met expression in stage I–II pancreatic adenocarcinoma: proposal for an immunostaining scoring method and correlation with poor prognosis. Histopathology. 2015;67(5):664–76.CrossRefPubMed
9.
10.
Han Y, Luo Y, Zhao J, et al. Overexpression of c-Met increases the tumor invasion of human prostate LNCaP cancer cells in vitro and in vivo. Oncol Lett. 2014;8(4):1618–24.PubMedPubMedCentral
11.
Leo C, Horn L-C, Einenkel J, et al. Tumor hypoxia and expression of c-met in cervical cancer. Gynecol Oncol. 2007;104(1):181–5.CrossRefPubMed
12.
Yoshida S, Harada T, Iwabe T, et al. Induction of hepatocyte growth factor in stromal cells by tumor-derived basic fibroblast growth factor enhances growth and invasion of endometrial cancer. J Clin Endocrinol Metab. 2002;87(5):2376–83.CrossRefPubMed
13.
Kanayama S, Yamada Y, Kawaguchi R, et al. Hepatocyte growth factor induces anoikis resistance by up-regulation of cyclooxygenase-2 expression in uterine endometrial cancer cells. Oncol Rep. 2008;19(1):117–22.PubMed
14.
Han SY, Jia S, Jia CR, et al. The correlation between expression of the hepatocyte growth factor and c-Met/hepatocyte growth factor receptor and the invasion and metastasis of uterine cervix cancer. Chin J Clin Oncol. 2006;12(1):1214–6.
15.
Refaat T, Donnelly ED, Sachdev S, et al. c-Met overexpression in cervical cancer, a prognostic factor and a potential molecular therapeutic target. Am J Clin Oncol. 2015.
16.
Peng J, Qi S, Wang P, et al. Diagnosis and prognostic significance of c-Met in cervical cancer: a meta-analysis. Dis Mark. 2016;2016:6594016.
17.
18.
Pillai MR, Halabi S, McKalip A, et al. The presence of human papillomavirus-16/-18 E6, p53, and Bcl-2 protein in cervicovaginal smears from patients with invasive cervical cancer. Cancer Epidemiol Biomark Prev. 1996;5(5):329–35.
19.
Dimitrakakis C, Kymionis G, Diakomanolis E, et al. The possible role of p53 and bcl-2 expression in cervical carcinomas and their premalignant lesions. Gynecol Oncol. 2000;77(1):129–36.CrossRefPubMed
20.
Liu L, Yu X, Guo X, et al. miR-143 is downregulated in cervical cancer and promotes apoptosis and inhibits tumor formation by targeting Bcl-2. Mol Med Rep. 2012;5(3):753–60.PubMed
21.
Cadamuro AC, Rossi AF, Maniezzo NM, et al. Helicobacter pylori infection: host immune response, implications on gene expression and microRNAs. World J Gastroenterol. 2014;20(6):1424–37.CrossRefPubMedPubMedCentral
22.
Curtale G, Mirolo M, Renzi TA, et al. Negative regulation of Toll-like receptor 4 signaling by IL-10–dependent microRNA-146b. Proc Natl Acad Sci U S A. 2013;110(28):11499–504.CrossRefPubMedPubMedCentral
23.
Hermeking H. MicroRNAs in the p53 network: micromanagement of tumour suppression. Nat Rev Cancer. 2012;12(9):613–26.CrossRefPubMed
24.
25.
He X, He L, Hannon GJ. The guardian’s little helper: microRNAs in the p53 tumor suppressor network. Cancer Res. 2007;67(23):11099–101.CrossRefPubMed
26.
Bhavna K, Arti Y, James L, et al. Dysrefulation of MicroRNA-34a expression in head and neck squamous cell carcinoma promotes tumor growth and tumor angiogenesis. PLoS ONE. 2012;7(5):e37601.CrossRef
27.
Bommer GT, Gerin I, Feng Y, et al. p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol. 2007;17(15):1298–307.CrossRefPubMed
28.
Chang TC, Wentzel EA, Kent OA, et al. Transactivation of miR-34a by p53 broadly inflences gene expression and promotes apoptosis. Mol Cell. 2007;26(5):745–52.CrossRefPubMedPubMedCentral
29.
Corney DC, Flesken-Nikitin A, Godwin AK, et al. MicroRNA-34b and microRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion independent growth. Cancer Res. 2007;67(18):8433–8.CrossRefPubMed
30.
Li B, Hu Y, Ye F, et al. Reduced miR-34a expression in normal cervical tissues and cervical lesions with high-risk human papillomavirus infection. Int J Gynecol Cancer. 2010;20(4):597–604.CrossRefPubMed
31.
Li L, Yuan L, Luo J, et al. MiR-34a inhibits proliferation and migration of breast cancer through down-regulation of Bcl-2 and SIRT1. Clin Exp Med. 2013;13:109–17.CrossRefPubMed
32.
Mohan M, Kumar V, Lackner AA, et al. Dysregulated miR-34a-SIRT1-acetyl p65 axis is a potential mediator of immune activation in the colon during chronic simian immunodeficiency virus infection of rhesus macaques. J Immunol. 2015;194:291–306.CrossRefPubMed
33.
Geng D, Song X, Ning F, et al. MiR-34a inhibits viability and invasion of human papillomavirus-positive cervical cancer cells by targeting E2F3 and regulating survivin. Int J Gynecol Cancer. 2015;25:707–13.CrossRefPubMed
34.
Kashat M, Azzouz L, Sarkar SH, et al. Inactivation of AR and Notch-1 signaling by miR-34a attenuates prostate cancer aggressiveness. Am J Transl Res. 2012;4:432–42.PubMedPubMedCentral
35.
36.
Alteri A, De Vito F, Messina G, et al. Cyclin D1 is a major target of miR-206 in cell differentiation and transformation. Cell Cycle. 2013;12(24):3781–90.CrossRefPubMedPubMedCentral
37.
Nie J, Ge X, Geng Y, Cao H, Zhu W, Jiao Y, Wu J, Zhou J, Cao J. miR-34a inhibits the migration and invasion of esophageal squamous cell carcinoma by targeting Yin Yang-1. Oncol Rep. 2015;34:311–7.PubMed
38.
Garofalo M, Jeon YJ, Nuovo GJ, et al. Correction: miR-34a/c-dependent PDGFR-alpha/beta downregulation Inhibits tumorigenesis and enhances TRAIL-induced apoptosis in lung cancer. PLoS ONE. 2015;10:e0131729.CrossRefPubMedPubMedCentral
39.
Li L. Regulatory mechanisms and clinical perspectives of miR-34a in cancer. J Cancer Res Ther. 2014;10:805–10.CrossRefPubMed
40.
Dang Y, Luo D, Rong M, et al. Underexpression of miR-34a in hepatocellular carcinoma and its contribution towards enhancement of proliferating inhibitory effects of agents targeting c-MET. PLoS ONE. 2013;8(4):e61054.CrossRefPubMedPubMedCentral
41.
Chen H, Wang J, Hu B, et al. MiR-34a promotes Fas-mediated cartilage endplate chondrocyte apoptosis by targeting Bcl-2. Mol Cell Biochem. 2015;406(1–2):21–30.CrossRefPubMed
42.
Wu S, He X, Li M, et al. MiRNA-34a overexpression inhibits multiple myeloma cancer stem cell growth in mice by suppressing TGIF2. Am J Transl Res. 2016;8(12):5433–43.PubMedPubMedCentral
43.
Sun TY, Xie HJ, Li Z, et al. MiR-34a regulates HDAC1 expression to affect the proliferation and apoptosis of hepatocellular carcinoma. Am J Transl Res. 2017;9(1):103–14.PubMedPubMedCentral
44.
Nohata N, Hanazawa T, Enokida H, et al. microRNA-1/133a and microRNA-206/133b clusters: dysregulation and functional roles in human cancers. Oncotarget. 2012;3(1):9–21.PubMedPubMedCentral
45.
Kondo N, Toyama T, Sugiura H, et al. miR-206 expression is down-regulated in estrogen receptor alpha-positive human breast cancer. Cancer Res. 2008;68(13):5004–8.CrossRefPubMed
46.
Song G, Zhang Y, Wang L. MicroRNA-206 targets notch3, activates apoptosis, and inhibits tumor cell migration and focus formation. J Biol Chem. 2009;284(46):31921–7.CrossRefPubMedPubMedCentral
47.
Sun C, Liu Z, Li S, et al. Down-regulation of c-Met and Bcl2 by microRNA-206, activates apoptosis, and inhibits tumor cell proliferation, migration and colony formation. Oncotarget. 2015;6(28):25533–74.CrossRefPubMedPubMedCentral
48.
Taulli R, Bersani F, Foglizzo V, Linari A, Vigna E, Ladanyi M, Tuschl T, Ponzetto C. The muscle-specific microRNA miR-206 blocks human rhabdomyosarcoma growth in xenotransplanted mice by promoting myogenic differentiation. J Clin Invest. 2009;119:2366–78.PubMedPubMedCentral
49.
Ewen ME, Lamb J. The activities of cyclin D1 that drive tumorigenesis. Trends Mol Med. 2004;10:158–62.CrossRefPubMed
50.
Zhou J, Tian Y, Li J, Lu B, Sun M, Zou Y, Kong R, Luo Y, Shi Y, Wang K, Ji G. miR-206 is down-regulated in breast cancer and inhibits cell proliferation through the up-regulation of cyclinD2. Biochem Biophys Res Commun. 2013;433(2):207–12.CrossRefPubMed
51.
Huang B, Zhai W, Hu G, et al. MicroRNA-206 acts as a tumor suppressor in bladder cancer via targeting YRDC.Am. J Transl Res. 2016;8(11):4705–15.
52.
Ren XL, He GY, Li XM, et al. MicroRNA-206 functions as a tumor suppressor in colorectal cancer by targeting FMNL2. J Cancer Res Clin Oncol. 2016;142(3):581–92.CrossRefPubMed
Metadata
Title
MiR-34a and miR-206 act as novel prognostic and therapy biomarkers in cervical cancer
Authors
Ai-Hua Chen
Yu-E Qin
Wen-Fan Tang
Jing Tao
Hua-mei Song
Manzhen Zuo
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2017
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-017-0431-9

Other articles of this Issue 1/2017

Cancer Cell International 1/2017 Go to the issue

Primary Research

RETRACTED ARTICLE: miR-484 suppresses proliferation and epithelial–mesenchymal transition by targeting ZEB1 and SMAD2 in cervical cancer cells

Primary Research

Repression of GPRC5A is associated with activated STAT3, which contributes to tumor progression of head and neck squamous cell carcinoma

Primary Research

Aberrantly methylated-differentially expressed genes and pathways in colorectal cancer

Correction

Correction to: The role of pparγ and autophagy in ros production, lipid droplets biogenesis and its involvement with colorectal cancer cells modulation

Research

Pleomorphism and drug resistant cancer stem cells are characteristic of aggressive primary meningioma cell lines

Primary Research

Hedgehog/Gli1 signaling pathway regulates MGMT expression and chemoresistance to temozolomide in human glioblastoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits